149 related articles for article (PubMed ID: 36175721)
21. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
22. Induction of acute lymphocytic leukemia differentiation by maintenance therapy.
Lin TL; Vala MS; Barber JP; Karp JE; Smith BD; Matsui W; Jones RJ
Leukemia; 2007 Sep; 21(9):1915-20. PubMed ID: 17611566
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene.
Dou L; Li J; Zheng D; Li Y; Gao X; Xu C; Gao L; Wang L; Yu L
Mol Biol Rep; 2013 Dec; 40(12):6811-9. PubMed ID: 24057258
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
25. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
26. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
27. Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Cattaneo F; Ammendola R; Esposito G
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924850
[TBL] [Abstract][Full Text] [Related]
28. Some biochemical characteristics of L1210 cell lines resistant to 6-mercaptopurine and 6-thioguanine and with increased sensitivity to methotrexate.
Strobel-Stevens JD; El Dareer SM; Trader MW; Hill DL
Biochem Pharmacol; 1982 Oct; 31(19):3133-7. PubMed ID: 6890814
[TBL] [Abstract][Full Text] [Related]
29. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
30. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
31. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia.
Bökkerink JP; Damen FJ; Hulscher MW; Bakker MA; De Abreu RA
Haematol Blood Transfus; 1990; 33():110-7. PubMed ID: 2323622
[No Abstract] [Full Text] [Related]
32. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
33. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
34. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
35. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
[TBL] [Abstract][Full Text] [Related]
36. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
37. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
38. [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink JP; de Abreu RA; Lippens RJ; Schouten TJ; de Vaan GA
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):55-60. PubMed ID: 3287684
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.
Lu X; Liu M; Yang J; Que Y; Zhang X
Clin Exp Immunol; 2022 Aug; 209(2):127-139. PubMed ID: 35867577
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]